Jane A Cauley1, Michelle E Danielson1, Guru Rajesh Jammy1, Doug C Bauer2, Rebecca Jackson3, Jean Wactawski-Wende4, Rowan T Chlebowski5, Kristine E Ensrud6,7,8, Robert Boudreau1. 1. Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15261. 2. University of California at San Francisco, San Francisco, California 94143. 3. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The Ohio State University, Columbus, Ohio 43210. 4. Department of Epidemiology and Environmental Health, University at Buffalo, State University of New York, Buffalo, New York 14260. 5. Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles Medical Center, Torrance, California 90502. 6. Department of Medicine and Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota 55455. 7. Department of Medicine, Minneapolis Veteran's Administration Health System, Minneapolis, Minnesota 55417. 8. Center for Chronic Disease Outcomes Research, Veteran's Administration Health Care System, Minneapolis, Minnesota 55417.
Abstract
Context: We hypothesize that endogenous sex steroids are associated with fracture risk independent of race/ethnicity. Design and Setting: We performed a nested case-control study within the prospective Women's Health Initiative Observational Study. Incident nonspine fractures were identified in 381 black, 192 Hispanic, 112 Asian, and 46 Native American women over an average of 8.6 years. A random sample of 400 white women who experienced an incident fracture was chosen. One control was selected per case and matched on age, race/ethnicity, and blood draw date. Bioavailable estradiol (BioE2), bioavailable testosterone (BioT), and sex hormone-binding globulin (SHBG) were measured using baseline fasting serum. Conditional logistic regression models calculated the odds ratio (OR) and 95% confidence interval (CI) of fracture across tertiles of hormone. Results: In multivariable and race/ethnicity-adjusted models, higher BioE2 (>8.25 pg/mL) and higher BioT (>13.3 ng/dL) were associated with decreased risk of fracture (OR, 0.65; 95% CI, 0.50 to 0.85; P trend = 0.001 and OR, 0.76; 95% CI, 0.60 to 0.96; P trend = 0.02, respectively). The interaction term between race/ethnicity and either BioE2 or BioT was not significant. There was no association between SHBG and fracture risk. In models stratifying by race/ethnicity, higher BioE2 was associated with a lower risk of fracture in both white women (OR, 0.56; 95% CI, 0.36 to 0.87) and black women (OR, 0.61; 95% CI, 0.39 to 0.96). Higher BioT was associated with a significantly lower fracture risk in only black women (OR, 0.65; 95% CI, 0.43 to 1.00), P trend = 0.03. Conclusions: Serum BioE2 and BioT are associated with fracture risk in older women irrespective of race/ethnicity and independent of established risk factors for fracture.
Context: We hypothesize that endogenous sex steroids are associated with fracture risk independent of race/ethnicity. Design and Setting: We performed a nested case-control study within the prospective Women's Health Initiative Observational Study. Incident nonspine fractures were identified in 381 black, 192 Hispanic, 112 Asian, and 46 Native American women over an average of 8.6 years. A random sample of 400 white women who experienced an incident fracture was chosen. One control was selected per case and matched on age, race/ethnicity, and blood draw date. Bioavailable estradiol (BioE2), bioavailable testosterone (BioT), and sex hormone-binding globulin (SHBG) were measured using baseline fasting serum. Conditional logistic regression models calculated the odds ratio (OR) and 95% confidence interval (CI) of fracture across tertiles of hormone. Results: In multivariable and race/ethnicity-adjusted models, higher BioE2 (>8.25 pg/mL) and higher BioT (>13.3 ng/dL) were associated with decreased risk of fracture (OR, 0.65; 95% CI, 0.50 to 0.85; P trend = 0.001 and OR, 0.76; 95% CI, 0.60 to 0.96; P trend = 0.02, respectively). The interaction term between race/ethnicity and either BioE2 or BioT was not significant. There was no association between SHBG and fracture risk. In models stratifying by race/ethnicity, higher BioE2 was associated with a lower risk of fracture in both white women (OR, 0.56; 95% CI, 0.36 to 0.87) and black women (OR, 0.61; 95% CI, 0.39 to 0.96). Higher BioT was associated with a significantly lower fracture risk in only black women (OR, 0.65; 95% CI, 0.43 to 1.00), P trend = 0.03. Conclusions: Serum BioE2 and BioT are associated with fracture risk in older women irrespective of race/ethnicity and independent of established risk factors for fracture.
Authors: J David Curb; Anne McTiernan; Susan R Heckbert; Charles Kooperberg; Janet Stanford; Michael Nevitt; Karen C Johnson; Lori Proulx-Burns; Lisa Pastore; Michael Criqui; Sandra Daugherty Journal: Ann Epidemiol Date: 2003-10 Impact factor: 3.797
Authors: Sundeep Khosla; B Lawrence Riggs; Richard A Robb; Jon J Camp; Sara J Achenbach; Ann L Oberg; Peggy A Rouleau; L Joseph Melton Journal: J Clin Endocrinol Metab Date: 2005-07-05 Impact factor: 5.958
Authors: N M Probst-Hensch; S A Ingles; A T Diep; R W Haile; F Z Stanczyk; L N Kolonel; B E Henderson Journal: Endocr Relat Cancer Date: 1999-06 Impact factor: 5.678
Authors: Hermien W Goderie-Plomp; Marjolein van der Klift; Willem de Ronde; Albert Hofman; Frank H de Jong; Huibert A P Pols Journal: J Clin Endocrinol Metab Date: 2004-07 Impact factor: 5.958
Authors: Jennifer S Lee; Andrea Z LaCroix; LieLing Wu; Jane A Cauley; Rebecca D Jackson; Charles Kooperberg; Meryl S Leboff; John Robbins; Cora E Lewis; Douglas C Bauer; Steven R Cummings Journal: J Clin Endocrinol Metab Date: 2008-03-11 Impact factor: 5.958
Authors: J A Cauley; A Z LaCroix; J A Robbins; J Larson; R Wallace; J Wactawski-Wende; Z Chen; D C Bauer; S R Cummings; R Jackson Journal: Osteoporos Int Date: 2009-05-13 Impact factor: 4.507
Authors: William Rosner; Susan E Hankinson; Patrick M Sluss; Hubert W Vesper; Margaret E Wierman Journal: J Clin Endocrinol Metab Date: 2013-03-05 Impact factor: 5.958
Authors: Jane A Cauley; Kristine Ruppert; Yinjuan Lian; Joel S Finkelstein; Carrie A Karvonen-Gutierrez; Sioban D Harlow; Joan C Lo; Sherri-Ann M Burnett-Bowie; Arun Karlamangla; Gail A Greendale Journal: J Clin Endocrinol Metab Date: 2019-06-01 Impact factor: 5.958
Authors: Konrad Pätzug; Nele Friedrich; Hanna Kische; Anke Hannemann; Henry Völzke; Matthias Nauck; Brian G Keevil; Robin Haring Journal: Bone Rep Date: 2017-08-18